Search Results for: approval

By Kuldip K. Ambastha On Thursday, January 5, 2023, the stock of NovoCure Limited (NVCR), an oncology company, rose by +68.5% for the trading day. The LUNAR study has shown that a medical device developed by NovoCure is able to improve, in a statistically significant way, the prospect of survival for people with late-stage lung …

Continue reading “What Caught Our Attention in the Investment World? – Week of January 3-6, 2023”

By Kuldip K. Ambastha The stock of BeiGene, Ltd. (BGNE), a commercial stage biopharmaceutical company focused on cancer treatment drugs, saw a +20.5% increase in price per share on Wednesday, October 12, 2022. Brukinsa (zanubrutinib) in its Phase 3 trial data showed highly positive results in people with chronic lymphocytic leukemia (CLL) or small lymphocytic …

Continue reading “What Caught Our Attention in the Investment World? – Week of October 10-14, 2022”

By Kuldip K. Ambastha Alphabet Inc. (GOOG), the parent company of Google, was a star performer on Wednesday February 2, 2022 when its stock delivered a +7.4% return for the trading day. The company’s earnings and revenue figures for the latest reporting quarter exceeded expectations. Furthermore, the company also announced a 20-for-1 stock split which …

Continue reading “What Caught Our Attention in the Investment World? – Week of January 31-February 4, 2022”

By Kuldip K. Ambastha Novavax, Inc. (NVAX), a clinical-stage vaccine company, had four negative daily returns and one positive daily return for its shares during this past trading week per the table displayed here. Worldwide, the coronavirus pandemic continues to be a serious public health issue, especially through the Delta and Omicron COVID-19 variants. Novavax …

Continue reading “What Caught Our Attention in the Investment World? – Week of December 27-31, 2021”

By Kuldip K. Ambastha On Monday, November 22, 2021, Vonage Holdings Corp. (VG), a leading telecommunications services corporation, delivered a return of +27.0% per share for the trading day. Why? The key catalyst here was an announcement from Telefonaktiebolaget LM Ericsson (ERIC), more commonly known as Ericsson. Over the weekend, Ericsson stated that it would …

Continue reading “What Caught Our Attention in the Investment World? – Week of November 22-26, 2021”

By Kuldip K. Ambastha Biogen Inc. (BIIB), a biotech company, had a memorable Monday of this past trading week. On Monday, June 7, 2021, Biogen had a +38.3% gain for the day on its stock. Biogen’s Alzheimer’s disease treatment was approved by the U.S. Food and Drug Administration (FDA) as part of an accelerated approval …

Continue reading “What Caught Our Attention in the Investment World? – Week of June 7-11, 2021”

By Kuldip K. Ambastha On Sunday, March 21, 2021, Canadian Pacific Railway Limited (CP) announced that it would be buying Kansas City Southern (KSU), for $29 billion ($25 billion in cash and equity, along with $4 billion in outstanding Kansas City Southern debt). The surprise announcement resulted in a +11.1% return for Kansas City Southern …

Continue reading “What Caught Our Attention in the Investment World? – Week of March 22-26, 2021”

By Kuldip K. Ambastha Biogen Inc. (BIIB) had a -7.5% return on Thursday, June 18, 2020. On this day, Biogen Inc. lost a legal dispute (over a patent) being heard by a U.S. district court. The patent dispute centered on a multiple sclerosis treatment drug called Tecfidera, which uses dimethyl fumarate as its main active …

Continue reading “What Caught Our Attention in the Investment World? – Week of June 15 – 19, 2020”

By Kuldip K. Ambastha and Anil K. Ambastha On October 22, 2019, Biogen Inc. (BIIB) delivered a 26.1% return for the day. This was the stock’s largest one-day percentage return in 23 years. Its Alzheimer’s drug (aducanumab) had previously been written off as a failure, but now will be getting a second chance at approval …

Continue reading “What Caught Our Attention in the Investment World? – Week of October 21-25, 2019”

By Kuldip K. Ambastha and Anil K. Ambastha Acadia Pharmaceuticals Inc. (ACAD) is a biopharmaceutical company which has Nuplazid (aka: pimavanserin) in its product pipeline. Nuplazid has been used by individuals suffering from Parkinson’s disease-linked psychosis. Acadia has now analyzed Nuplazid in relation to individuals suffering from dementia-related psychosis. Currently, no approved drugs exist in …

Continue reading “What Caught Our Attention in the Investment World? – Week of September 9-13, 2019”